Pediatrix Medical Group, Inc. Stock Price, News & Analysis

Mednax, Inc. (NYSE: MD) endorses the CDC's COVID-19 vaccination recommendations, emphasizing the importance of safeguarding at-risk populations, particularly pregnant women and children. With over 400 million doses administered in the U.S., the firm highlights that unvaccinated individuals account for approximately 90% of COVID-19 deaths. This position aligns with other prominent medical associations dedicated to maternal and pediatric care. Mednax's commitment to improving patient outcomes is reinforced through its extensive network of over 2,300 healthcare professionals across 39 states and Puerto Rico.

Brave Care, a pediatric healthcare platform, raised $25M in a funding round led by Mednax, Inc. (NYSE: MD). The new investment aims to expand Brave Care's pediatric clinics across the U.S., enhancing access to affordable child healthcare. Currently operating clinics in Portland, OR and Fayetteville, NC, the company plans to open over 100 new facilities. Brave Care seeks to provide quality urgent care, alleviating the burden on emergency rooms for parents of sick children. The investment could significantly enhance patient care and operational capabilities.

Mednax (NYSE: MD) has announced a $20 million investment in Brave Care, aiming to develop innovative pediatric primary and urgent care clinics across the United States. This partnership will leverage Brave Care's advanced technology and Mednax's clinical expertise, enhancing pediatric care delivery. The investment grants Mednax a minority stake in Brave Care, with plans to open over 100 clinics and rebrand existing facilities under the Pediatrix name. The collaboration signifies a commitment to improving healthcare accessibility for children nationwide.

Mednax, Inc. (NYSE: MD), a leader in specialized maternal care, reports a record high of pregnant patients critically ill with COVID-19, primarily unvaccinated, as the Delta variant surges. The company emphasizes the importance of vaccination, citing severe complications for high-risk patients. Obstetrix, with nearly 550 clinicians, provides extensive maternal services nationwide, aiming to improve outcomes for critically ill pregnant women. Clinical research continues to monitor COVID-19 effects on pregnant women, with a strong endorsement for vaccination to prevent severe illness.

Mednax, Inc. (NYSE: MD) announced it will present at Morgan Stanley's 19th Annual Global Healthcare Conference on September 15, 2021, at 12:30 p.m. ET. The presentation will be accessible via live audio webcasts. Mednax is a national medical group with over 2,300 physicians across 39 states and Puerto Rico, focusing on enhancing patient outcomes through evidence-based care and telehealth programs. Founded in 1979, Mednax is committed to high-quality, cost-effective healthcare.

Mednax, Inc. (NYSE: MD) reported earnings of $0.36 per share for Q2 2021, with adjusted EPS at $0.41. Net revenue reached $473 million, up from $415.4 million year-over-year. The net income from continuing operations was $31 million, with an adjusted EBITDA of $66 million. The increase in revenue was driven by strong patient volume trends, with same-unit revenue growth of 13.4%. Operating expenses rose, including salaries and benefits totaling $317 million. Cash and equivalents decreased to $338.2 million. Mednax will hold an investor call to discuss results.

Mednax, Inc. (NYSE: MD) will hold an investor conference call on August 6, 2021, at 9:00 a.m. ET to discuss its operational results for the quarter and six months ending June 30, 2021. A detailed press release will be provided that morning. The call will be accessible via Mednax's website. Established in 1979, Mednax comprises over 2,300 physicians across 39 states and Puerto Rico, focusing on enhancing patient care through evidence-based methods and telehealth. Forward-looking statements in the PR highlight potential risks and uncertainties affecting future performance.

Mednax, Inc. (NYSE: MD) announced that CVS Aetna has voluntarily dismissed its litigation against the company, concluding a case initiated in 2018. This dismissal was officially filed in court on July 14. CEO Mark S. Ordan expressed relief over the resolution, emphasizing Mednax's commitment to patient care and hope for a positive relationship with CVS Aetna moving forward. Mednax is a national medical group focused on providing high-quality, cost-effective physician services across specialties.

Mednax, Inc. (NYSE: MD) reported Q1 2021 earnings of $0.06 per share, with an adjusted EPS of $0.24. Net revenue rose to $447 million, a 1.4% increase year-over-year. Patient volumes were affected by COVID-19, but a 3.6% increase in same-unit revenue was noted. Adjusted EBITDA improved to $45.5 million, aided by provider relief funds. Cash reserves fell to $270 million after redeeming $750 million in senior notes. Despite challenges, Mednax remains focused on operational efficiency and support for clinicians.